Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector
In an interview with Adrian van den Hoven, Director General of Medicines for Europe, meaningful progress made in 2025 is highlighted, including the political agreement on the new EU ph...
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
Here we to examine how subcutaneous diuretic therapy is poised to transform the management of heart failure edema. SQ Innovation announced on April 28, 2026, that its Lasix® ONYU subcutaneous furosemide drug-device combination has achieved CE Marking under the EU Medical Device Regulation and has...
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced Predictive Insights
TikTok Opioid Overdose Forecasting is gaining attention as a powerful new approach to public health surveillance. A new study shows that comments on opioid-related TikTok videos can significantly improve predictions of synthetic opioid deaths, reducing forecasting errors by up to 37% compared wit...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program for Innovative Techno...
The European Medicines Agency (EMA) has launched a pilot programme to deliver breakthrough medical device access for high-risk technologies that address unmet medical needs. Starting 28 April 2026, the initiative offers enhanced scientific advice and priority access to expert panels for developer...
Medical Device Innovation South Africa: Breaking Down Systemic Barriers
Medical device innovation South Africa is hindered by deep structural obstacles that prevent locally developed technologies from reaching patients, despite the country’s considerable technical expertise. South Africa’s medical technology sector remains trapped in a cycle of heavy import dependenc...
Expanding Access to Hormonal IUDs in South Africa through Generic Innovation
The launch of AVIBELA marks a significant milestone for hormonal IUD South Africa, introducing the country’s first generic levonorgestrel 52 mg intrauterine device. Developed by Medicines360 and commercialized in partnership with Pharma Dynamics, AVIBELA is more than 99% effective at preventing p...







